Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Biogen Buys Stromedix
by Lisa M. Jarvis
February 20, 2012
| A version of this story appeared in
Volume 90, Issue 8
In a deal worth up to $562.5 million, Biogen Idec is acquiring privately held Stromedix. Biogen gains STX-100, a monoclonal antibody poised to enter Phase II trials as an idiopathic pulmonary fibrosis treatment. Stromedix investors will receive $75 million up front and up to $487.5 million more contingent on reaching certain milestones for STX-100. Stromedix was founded in 2005 by Biogen’s former head of research, Michael Gilman. The firm subsequently licensed STX-100 from Biogen, completed Phase I trials, and developed biomarkers to facilitate patient selection for future studies.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter